Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Net Income (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Net Income data on record, last reported at -$38.8 million in Q4 2025.

  • For Q4 2025, Net Income fell 3.03% year-over-year to -$38.8 million; the TTM value through Dec 2025 reached -$101.6 million, up 22.03%, while the annual FY2025 figure was -$101.6 million, 22.03% up from the prior year.
  • Net Income reached -$38.8 million in Q4 2025 per TNGX's latest filing, down from $15.9 million in the prior quarter.
  • Across five years, Net Income topped out at $15.9 million in Q3 2025 and bottomed at -$39.8 million in Q1 2025.
  • Average Net Income over 5 years is -$24.8 million, with a median of -$26.8 million recorded in 2023.
  • Peak YoY movement for Net Income: plummeted 157442.58% in 2021, then soared 154.42% in 2025.
  • A 5-year view of Net Income shows it stood at -$22.0 million in 2021, then tumbled by 31.82% to -$29.1 million in 2022, then decreased by 5.82% to -$30.8 million in 2023, then fell by 22.48% to -$37.7 million in 2024, then decreased by 3.03% to -$38.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$38.8 million in Q4 2025, $15.9 million in Q3 2025, and -$38.8 million in Q2 2025.